Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Breckenridge Pharmaceutical, Inc. has signed a new-product agreement with PTS Pharma, LLC. under which PTS will support a technology transfer to Towa Pharmaceutical Europe, S.L. of a complex "For Suspension" product developed by PTS.
read more
Breckenridge Pharmaceutical, Inc. announced the signing of a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.
read more
Breckenridge announced it has entered into a multi-product agreement with Sam Chun Dang Pharm, under which Breckenridge and SCD expect to develop and commercialize at least seven ANDAs.
read more
Breckenridge Pharmaceutical, the U.S. subsidiary of Towa International, announced a partnership with Maiva Pharma focused on sterile injectable products to be supplied primarily to hospitals and clinics.
read more
Wednesday, October 04, 2017
Breckenridge Pharmaceutical has acquired five Abbreviated New Drug Applications (ANDAs) from Nostrum Laboratories.
read more
Friday, February 27, 2015
Brazil, a signature country of South America just surpassed 200 million residents. It is the main economy in Latin America and one of the most important at world level, regionally considered industrialized in spite of the variety of income, from very...
read more
Monday, November 27, 2017
Brammer Bio announced the completion of renovations and launch of its late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, Massachusetts for gene therapy products.
read more
Brammer Biopharmaceuticals has announced its merger with Florida Biologix to create a cell and gene therapy biologics contract development and manufacturing organization (CDMO). The merged company, Brammer Bio, will combine deep technical expertise ...
read more
Monday, September 18, 2017
Brammer Bio announced completion of its clinical capacity expansion in Alachua, Florida.
read more
Thursday, September 27, 2018
Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
read more
BrainStorm has begun training City of Hope's Center for Biomedicine and Genetics to produce NurOwn adult stem cells for the ALS Phase 3 clinical study.
read more
Wednesday, January 03, 2018
BrainStorm Cell Therapeutics has received GMP approval from the Israel Ministry of Health for its Israeli contract manufacturing facility.
read more
Tuesday, November 12, 2024
BrainStorm Cell Therapeutics Inc. has entered into a Memorandum of Understanding (MOU) with Pluri Inc. to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS).
read more
Tuesday, December 07, 2021
BrainStorm Cell Therapeutics Inc., a developer of cellular therapies for neurodegenerative diseases, and Catalent, a provider of services enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of ...
read more
BrainStorm Cell Therapeutics has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute as a second U.S. manufacturing site to supply NurOwn.
read more